Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma.

Oncotarget - 1 Apr 2011

Koomen John M, Smalley Keiran S M

Abstract excerpt

The discovery of activating BRAF V600E mutations in 50% of all melanoma patients and the development of small molecule BRAF inhibitors looks set to revolutionize the therapy of disseminated melanoma. However, in the recent clinical trial of the BRAF inhibitor, vemurafenib (PLX4032), a significant percentage of BRAF V600E mutant melanoma patients did not meet the RECIST criteria for a response. Recent work from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Comprehension
Share to Drug Resistance, Neoplasm
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutant Proteins

Share to Proteome

Share to Proteomics

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 21505227
DOI: 10.18632/oncotarget.263
PMCID: PMC3248164

Genes

BRAF
PTEN

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma.PMID 21505227Read ↗

PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic MelanomaSemantic proximity Read ↗

The Hidden Story on Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma – Association with Clinical Outcome and Tumor PhenotypesSemantic proximity Read ↗

Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanomaSemantic proximity Read ↗

Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapySemantic proximity Read ↗

Multi-omics analysis delineates resistance mechanisms associated with BRAF inhibition in melanoma cells.Semantic proximity Read ↗

Differential Gene Expression Common to Acquired and Intrinsic Resistance to BRAF Inhibitor Revealed by RNA-Seq AnalysisSemantic proximity Read ↗

Proteomic profile and in silico analysis in metastatic melanoma with and without BRAF mutation.Semantic proximity Read ↗

ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma.Semantic proximity Read ↗

Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.Semantic proximity Read ↗

Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.Semantic proximity Read ↗

Quantitative Tyr Phosphoproteomic Analyses Identify Cholesterol as a Master Regulator of the Tumor Adaptive Resistance to MAPK InhibitionSemantic proximity Read ↗

Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ Specificity and Treatment Resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.